Abstract 346P
Background
ET is the mainstay treatment (tx) for HR+ eBC but they have persistent side effects that negatively affect QoL, leading to early tx discontinuation and compromising outcomes. We describe the incidence of ET toxicity and its QoL impact in CANTO.
Methods
CANTO (NCT01993498) is a prospective, longitudinal cohort study enrolling pts with invasive (cT0-cT3, cN0-3, no metastases) BC from 26 French cancer centres. Pts with HR+, HER2– eBC treated with adj ET were followed for the first 3 years (yrs) after eBC diagnosis. Pt demographics, clinical data, adherence, symptoms and QoL were collected. Questionnaires were administered at baseline (BL), 3–6 months (mo; M0) after primary surgery, chemotherapy or radiotherapy completion (whichever came last), and 12 mo, 36 mo and 60 mo after M0. Descriptive analyses were conducted for frequency of symptoms and mean/median QoL questionnaires summary scores.
Results
Of the 5564 pts who met the inclusion criteria (median age: 57 yrs), 63% were post-menopausal and 52% had stage I eBC at diagnosis. The table shows QoL and toxicity data. Global and functioning QoL remained high at BL and during tx. BC-specific symptoms persisted during tx. Pain was the most prevalent toxicity in the first 3 yrs; prevalence of muscular and joint pain increased over time. Mean intensity of global, muscular and joint pain all remained high over the course of ET (median intensity: ∼6 [0–10 scale]). ET adherence was 81–93% over time; in the first 3 yrs, 23% switched ET and 7% discontinued adj ET; toxicity was the main reason cited. Table: 346P
BL | M0 | 12 mo | 36 mo | |
Mean EORTC QLQ-C30 | 83 | 80 | 79 | 80 |
Global health status | 68 | 68 | 66 | 66 |
Physical functioning | 91 | 85 | 84 | 85 |
Role functioning | 87 | 80 | 82 | 83 |
Emotional functioning | 65 | 72 | 70 | 71 |
Cognitive functioning | 82 | 79 | 77 | 78 |
Social functioning | 91 | 83 | 85 | 86 |
Insomnia | 43 | 41 | 43 | 42 |
Fatigue | 28 | 36 | 35 | 34 |
Pain | 15 | 28 | 30 | 29 |
Mean EORTC QLQ-BR23 | ||||
Body image | 88 | 75 | 77 | 79 |
Future perspective | 49 | 56 | 61 | 64 |
Sexual functioning | 26 | 26 | 26 | 24 |
Breast symptoms | 13 | 26 | 20 | 16 |
Systemic therapy side effects | 11 | 20 | 19 | 18 |
Arm symptoms | 9 | 21 | 19 | 17 |
Toxicity, % | ||||
Global and back pain | - | 71 | 74 | 72 |
Muscular and back | - | 32 | 36 | 38 |
Joint and back | - | 59 | 68 | 70 |
Conclusions
While global and functional QoL remained high in the first 3 yrs after eBC diagnosis, BC-specific symptoms slightly increased/persisted during ET. This study confirmed long-term toxicity of ET, particularly pain. Better management of symptoms and supportive interventional strategies are needed to further improve QoL in eBC.
Clinical trial identification
NCT01993498, first posted November 25, 2013.
Editorial acknowledgement
Research support for third-party writing assistance for this abstract, furnished by Eleanor Porteous, MSc, of Health Interactions, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Legal entity responsible for the study
F. Hoffmann-La Roche Ltd.
Funding
F. Hoffmann-La Roche Ltd.
Disclosure
A. Bertaut: Non-Financial Interests, Personal, Other, Research funding: Support for third-party writing assistance from F. Hoffmann-La Roche Ltd: F. Hoffmann-La Roche Ltd. T. Badovinac Crnjevic: Financial Interests, Personal, Full or part-time Employment: F. Hoffmann-La Roche Ltd/ Genentech; Financial Interests, Personal, Stocks/Shares: F. Hoffmann-La Roche Ltd; Non-Financial Interests, Personal, Other, Research funding: Support for third-party writing assistance from F. Hoffmann-La Roche Ltd: F. Hoffmann-La Roche Ltd. A. Martin, C. Gaudin: Non-Financial Interests, Personal, Other, Research funding: Support for third-party writing assistance: F. Hoffmann-La Roche Ltd. L. Chen: Financial Interests, Personal, Full or part-time Employment: Genentech, Inc.; Financial Interests, Personal, Stocks/Shares: F. Hoffmann-La Roche Ltd; Non-Financial Interests, Personal, Other, Research funding: Support for third-party writing assistance: F. Hoffmann-La Roche Ltd.
Resources from the same session
393P - Real-world (RW) use patterns, effectiveness, and tolerability of sacituzumab govitecan (SG) for second-line (2L) and later treatment of metastatic triple-negative breast cancer (mTNBC)
Presenter: Kevin Kalinsky
Session: Poster session 03
394P - CDK4/6 inhibitors in metastatic breast cancer: An Italian real-world experience
Presenter: Francesco Pantano
Session: Poster session 03
395P - Interim analysis (IA) of the giredestrant (G) + ipatasertib (IPAT) arm in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with oestrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC)
Presenter: Kyung Jung
Session: Poster session 03
396P - Real-world treatment and survival outcomes in previously untreated patients with metastatic triple-negative breast cancer (mTNBC) in the United States (US)
Presenter: Kevin Punie
Session: Poster session 03
398P - A phase Ib/II study of IN10018/FAKi in combination with pegylated liposomal doxorubicin (PLD) and toripalimab in metastatic triple-negative breast cancer (TNBC): IN10018-010
Presenter: Xichun Hu
Session: Poster session 03
399P - Results from a first-in-human phase Ia/b study of LX-039, an oral selective estrogen receptor (ER) degrader (SERD), in postmenopausal patients with ER+, HER2- advanced breast cancer (ABC)
Presenter: weina shen
Session: Poster session 03
400P - The impact of CDK4/6 inhibitors on bone health: An Italian real-world experience
Presenter: Roberta Scafetta
Session: Poster session 03
401P - Utidelone in combination with etoposide and bevacizumab in HER2-negative breast cancer with brain metastasis (UTOBIA-BM): A prospective, single-arm, phase II trial
Presenter: Yehui Shi
Session: Poster session 03
402P - First-line ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without visceral crisis from the phase II RIGHT choice study
Presenter: Hamdy Azim
Session: Poster session 03